Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer
|ClinicalTrials.gov Identifier: NCT01490749|
Recruitment Status : Active, not recruiting
First Posted : December 13, 2011
Last Update Posted : March 13, 2018
The purpose of this study is to test the drug RAD001 in combination with another chemotherapy drug, Carboplatin, as well as radiation therapy in the treatment of esophageal cancer. Because RAD001 has not been used in this combination before, it is not clear which dose will be best when used in combination.
The standard of care for patients who have esophageal cancer that has not moved to other areas of the body (non-metastatic) includes a combination of chemotherapy, radiation therapy and possibly surgery. If the patient chooses to participate in this study, the patient will receive chemotherapy and radiation therapy. The patient will possibly also have surgery to have the cancer removed. This decision will be made by the treating physicians. All of the chemotherapy the patient will receive on the study is considered standard chemotherapy for esophagus cancer. The investigators do not know as of yet if the drug called RAD001 will help improve the treatment for patients with this disease. RAD001 is a pill that has been used in many other types of cancer and has been proven to be effective in other cancers such as kidney cancer.
|Condition or disease||Intervention/treatment||Phase|
|Esophageal Cancer Neoplasms, Esophageal||Drug: RAD001 Drug: XELOX Drug: Carboplatin Radiation: Radiation||Phase 1|
Esophageal cancer is the sixth most common cause of cancer-related death worldwide. Recent medical advances have led to small improvements in survival, but the overall rate of survival remains low, making new treatment approaches necessary.
Chemotherapy drugs and radiation therapy are often both used in treating esophageal cancer. The combination of oxaliplatin and capecitabine (XELOX) is a commonly used chemotherapy combination. Sometimes chemotherapy is given as an "induction" therapy, before the radiation is given.
The drug RAD001 is a targeted drug that acts specifically on a protein inside cells (called mTOR), which is important for cancer development. The combination of RAD001 and radiation therapy has been shown to improve anti-cancer effects.
This study will look for the ideal dose of RAD001 when given in combination with radiation therapy after induction chemotherapy with XELOX, and test the anticancer effects of this treatment approach in patients with esophageal cancer.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||17 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I/IIB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy and Dose Escalation of RAD001 in Patients With Esophageal Cancer|
|Actual Study Start Date :||February 2012|
|Estimated Primary Completion Date :||March 2019|
|Estimated Study Completion Date :||May 2020|
Patients receive XELOX comprising oxaliplatin intravenously (IV) over 120 minutes on day 1 and capecitabine orally (PO) twice daily (BID) on days 1-14. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo radiotherapy (RT) 5 days a week for up to 6 weeks. Patients also receive carboplatin IV over 15 minutes to 24 hours once weekly for 5-6 weeks and RAD001 PO every other day (QOD) or once daily (QD) for 5-6 weeks during radiation therapy (RT). Patients with resectable disease undergo surgery.
Dose escalation for Phase I; dose for Phase II to be determined after Phase I is completed.
Other Name: EverolimusDrug: XELOX
Patients will receive two cycles of XELOX.
Other Names:Drug: Carboplatin
Given on a 3 weeks on and 1 week off schedule.
Other Name: ParaplatinRadiation: Radiation
1.8 Gy to 36 Gy; 3 fields or laterals to 50.4 Gy.
- Phase I portion to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of RAD001 in combination with radiation [ Time Frame: within one month after surgery ]
- Rate of surgical pathologic complete remission (pCR) (absence of evidence of cancer after surgery) [ Time Frame: within one month from surgery ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01490749
|United States, Georgia|
|Emory University Hospital Midtown|
|Atlanta, Georgia, United States, 30308|
|Emory University Winship Cancer Institute|
|Atlanta, Georgia, United States, 30322|
|United States, Tennessee|
|Nashville, Tennessee, United States, 37232|
|Principal Investigator:||Nabil F. Saba, MD||Emory University Winship Cancer Institute|